Altimmune, Inc. (NASDAQ:ALT) Q2 2022 Results Conference Call August 11, 2022 8:30 AM ET
Company Participants
Richard Eisenstadt - Chief Financial Officer
Vipin Garg - President and Chief Executive Officer
Scot Roberts - Chief Scientific Officer
Scott Harris - Chief Medical Officer
Conference Call Participants
Seamus Fernandez - Guggenheim
Yasmeen Rahimi - Piper Sandler
Roger Song - Jefferies
Mayank Mamtani - B. Riley
Jon Welandon - JMP Securities
Patrick Trucchio - H.C. Wainwright
Operator
Good day, ladies and gentlemen, and welcome to the Altimmune, Inc. Q2 Financial Results Conference all. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this call is being recorded.
I would now like to introduce your host for today’s conference call. Rich Eisenstadt, Chief Financial Officer of Altimmune. Richard you may begin.
Richard Eisenstadt
Thank you, Carlo and good morning, everyone. Thank you for participating in Altimmune’s second quarter 2022 financial results conference call. Members of the Altimmune team joining me on the call today are Vipin Garg, our Chief Executive Officer, Scot Roberts, our Chief Scientific Officer and Scott Harris, our Chief Medical Officer.
Following the prepared remarks, we will hold a question-and-answer session. A press release with our second quarter 2022 financial results was issued this morning and can be found on the Investor Relations section of the Company’s website.
Before we begin, I would like to remind everyone that remarks about future expectations, plans, and prospects constitute Forward-Looking Statements for purposes of Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these Forward-Looking Statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. Including those related to the ongoing conflict in Ukraine, COVID-19, and the
- Read more current ALT analysis and news
- View all earnings call transcripts